NCT05968326 2026-03-12
IMCODE003
Genentech, Inc.
Phase 2 Recruiting
Clinical Trials
31 trialsNCT06901531 2026-03-11
LUCERNA
Astellas Pharma Inc
Phase 3 Recruiting
NCT06902545 2026-03-11
A Study to Observe the Safety of VYLOY (Zolbetuximab) in People in South Korea With Gastric or Gastroesophageal Junction Cancer.
Astellas Pharma Inc
Recruiting
NCT07023315 2026-02-11
A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma
Akeso
Phase 3 Recruiting
NCT07385703 2026-02-04
Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3 Not yet recruiting
NCT06048081 2025-09-10
Early Access Program for Zolbetuximab
Astellas Pharma Inc
Available
NCT05892926 2025-07-20
HER2-positive Locally Advanced/Metastatic Gastric and/or Gastroesophageal Junction (GEJ) Adenocarcinoma in Russia
AstraZeneca
Completed
NCT06942767 2025-04-27
Combination of QLS31905, QL2107 and Chemotherapy as First-line Therapy in CLDN18.2-positive Unresectable Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Qilu Pharmaceutical Co., Ltd.
Phase 2 Not yet recruiting
NCT01010945 2024-11-21
Erlotinib, Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Cancer
Astellas Pharma Inc
Phase 1 Completed
NCT04086758 2024-11-20
A Pharmacokinetic Study of Zolbetuximab (IMAB362) in Chinese Subjects With Locally Advanced Unresectable or Metastatic Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma
Astellas Pharma Inc
Phase 1 Completed
NCT05964543 2023-07-28
The Safety and Efficacy of Q-1802 Combined With XELOX in Gastrointestinal Tumors
QureBio Ltd.
Phase 1/2 Unknown
NCT02987829 2021-04-23
Phase 1/2A Study of TRC253, an Androgen Receptor Antagonist, in Metastatic Castration-resistant Prostate Cancer Patients
Tracon Pharmaceuticals Inc.
Phase 1/2 Completed
NCT02195180 2018-07-27
Efficacy and Safety of L-asparaginase Encapsulated in RBC Combined With Gemcitabine or FOLFOX in 2nd Line for Progressive Metastatic Pancreatic Carcinoma
ERYtech Pharma
Phase 2 Completed
NCT02125240 2018-07-16
ICWIP
Betta Pharmaceuticals Co., Ltd.
Phase 3 Unknown
NCT00548548 2017-06-14
AVAGAST
Genentech, Inc.
Phase 3 Completed
NCT01665417 2017-02-08
Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma
Betta Pharmaceuticals Co., Ltd.
Phase 4 Unknown
NCT00499850 2016-08-25
Phase I FOLFOX Combination
Sanofi
Phase 1 Completed
NCT00507091 2016-08-25
Phase I Irinotecan, 5-Fluorouracil and Leucovorin Combination
Sanofi
Phase 1 Completed
NCT01011751 2015-07-30
Treatment of Hot Flushes Caused by Leuprorelin 11.25 mg in Prostate Adenocarcinoma
Takeda
Phase 3 Completed
NCT02103257 2015-04-29
Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma
Betta Pharmaceuticals Co., Ltd.
Phase 4 Unknown
NCT00998322 2015-04-10
A Study of REOLYSIN® in Combination With Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma
Oncolytics Biotech
Phase 2 Completed
NCT02204046 2014-07-30
Biodistribution Study With 186 Re-labelled Humanised Monoclonal Antibody BIWA 4 in Patients With Adenocarcinoma of the Breast
Boehringer Ingelheim
Phase 1 Completed
NCT02194556 2014-07-18
Sequential and Maintenance Icotinib Plus Chemotherapy Versus Icotinib Maintenance After Chemotherapy in Advanced NSCLC
Betta Pharmaceuticals Co., Ltd.
Phase 4 Unknown
NCT01301612 2014-07-14
Study of Nimotuzumab, Radiation Therapy and Cisplatin Versus Radiation Therapy and Cisplatin for Treatment of Stage IB e IVA UCC(CORUS)
Eurofarma Laboratorios S.A.
Phase 2 Withdrawn
NCT01253525 2014-06-18
Study of Weekly Paclitaxel With Ramucirumab in Participants With Advanced Gastric Adenocarcinomas
Eli Lilly and Company
Phase 1 Completed
NCT01124786 2014-04-17
A Study Comparing CO-1.01 With Gemcitabine as First Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma (LEAP)
Clovis Oncology, Inc.
Phase 2 Completed
NCT01830322 2013-08-14
Safety and Effectiveness Study of CPI-613 and/or Gemcitabine to Treat Metastatic Pancreatic Cancer
Cornerstone Pharmaceuticals
Phase 2 Withdrawn
NCT00292864 2012-06-07
Safety Assessment of One-hour Infusions of SNS-032 for the Treatment of Select Advanced Solid Tumors
Sunesis Pharmaceuticals
Phase 1 Completed
NCT00140075 2011-05-26
Adjuvant Epirubicin/Cytoxan Followed By A Taxane VS. Epirubicin/Taxane As Treatment For Node-Positive Breast Cancer
Pfizer
Phase 3 Completed
NCT00191503 2007-01-26
Gemcitabine and Pemetrexed in Primary Unknown Adenocarcinoma
Eli Lilly and Company
Phase 2 Completed
NCT00051675 2005-06-24
Phase I Study of a Monoclonal Antibody for Treatment of Advanced Adenocarcinomas
XOMA (US) LLC
Phase 1 Completed